The prominent role of the S100A8/S100A9-CD147 axis in the progression of penile cancer.
CD147
HPV-related cancer
S100A8
S100A9
calprotectin
myeloid-derived suppressor cells
neutrophils
penile cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2022
accepted:
20
09
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Currently, no established biomarkers are recommended for the routine diagnosis of penile carcinoma (PeCa). The rising incidence of this human papillomavirus (HPV)-related cancer entity highlights the need for promising candidates. The Calprotectin subunits S100A8 and S100A9 mark myeloid-derived suppressor cells in other HPV-related entities while their receptor CD147 was discussed to identify patients with PeCa at a higher risk for poor prognoses and treatment failure. We thus examined their expression using immunohistochemistry staining of PeCa specimens from 74 patients on tissue microarrays of the tumor center, the invasion front, and lymph node metastases. Notably, whereas the tumor center was significantly more intensively stained than the invasion front, lymph node metastases were thoroughly positive for both S100 subunits. An HPV-positive status combined with an S100A8
Identifiants
pubmed: 36303837
doi: 10.3389/fonc.2022.891511
pmc: PMC9592847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
891511Informations de copyright
Copyright © 2022 Mohr, Zwick, Hans, Bley, Braun, Khalmurzaev, Matveev, Loertzer, Pryalukhin, Hartmann, Geppert, Loertzer, Wunderlich, Naumann, Kalthoff, Junker, Smola and Lohse.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer LM declared a shared affiliation, with no collaboration, with some of the authors AH and C-IG to the handling editor at the time of review.
Références
Eur Urol. 2016 May;69(5):953-61
pubmed: 26762611
Pathol Int. 2006 Jul;56(7):359-67
pubmed: 16792544
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
J Proteome Res. 2007 Jun;6(6):2143-51
pubmed: 17451265
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 May;119(5):553-65
pubmed: 25747176
BMC Cancer. 2014 Oct 08;14:751
pubmed: 25296855
Front Oncol. 2021 Sep 10;11:744889
pubmed: 34568077
Nat Med. 2014 Jun;20(6):676-81
pubmed: 24859530
J Immunol Methods. 2019 Oct;473:112644
pubmed: 31404549
Cancer Res. 2013 Jan 1;73(1):172-83
pubmed: 23135911
Signal Transduct Target Ther. 2021 Jan 12;6(1):12
pubmed: 33436555
Front Immunol. 2018 Jun 11;9:1253
pubmed: 29942303
BMC Urol. 2018 May 29;18(1):50
pubmed: 29843769
JCI Insight. 2018 Oct 18;3(20):
pubmed: 30333307
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
Nat Rev Dis Primers. 2021 Feb 11;7(1):11
pubmed: 33574340
Lancet Oncol. 2019 Jan;20(1):145-158
pubmed: 30573285
Nat Commun. 2020 May 1;11(1):2124
pubmed: 32358507
Cancer Manag Res. 2018 Sep 20;10:3753-3764
pubmed: 30288106
J Dent Res. 2018 Jun;97(6):674-682
pubmed: 29443623
Inflamm Res. 2018 Oct;67(10):801-812
pubmed: 30083975
J Leukoc Biol. 2009 Sep;86(3):557-66
pubmed: 19451397
Trends Immunol. 2019 Jul;40(7):565-583
pubmed: 31160207
Cancer Lett. 2013 Jul 28;335(2):380-6
pubmed: 23474495
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nat Rev Cancer. 2020 Sep;20(9):485-503
pubmed: 32694624
Oncotarget. 2016 Mar 22;7(12):14029-47
pubmed: 26883112
J Surg Res. 2010 May 15;160(2):260-7
pubmed: 19286191
J Cell Mol Med. 2019 Feb;23(2):954-966
pubmed: 30421493
Virchows Arch. 2014 Sep;465(3):299-312
pubmed: 25027580
Nature. 2019 Nov;575(7783):519-522
pubmed: 31666702
Urol Oncol. 2014 Jan;32(1):53.e1-8
pubmed: 24239463
Cancers (Basel). 2019 Nov 16;11(11):
pubmed: 31744072
Front Immunol. 2022 Apr 06;13:810471
pubmed: 35464411
Vaccine. 2012 Nov 20;30 Suppl 5:F55-70
pubmed: 23199966
Gynecol Oncol. 2009 Jan;112(1):248-56
pubmed: 19007971
Eur J Cancer. 2020 Jul;134:52-59
pubmed: 32460181
IARC Sci Publ. 2008;(160):1-837
pubmed: 19388204
Int J Mol Sci. 2019 Apr 22;20(8):
pubmed: 31013576
Transl Oncol. 2022 Jan;15(1):101267
pubmed: 34773828
Mol Cancer Res. 2004 Feb;2(2):73-80
pubmed: 14985463
Sci Rep. 2016 Sep 09;6:32804
pubmed: 27608940
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Front Microbiol. 2018 Mar 07;9:392
pubmed: 29563902
Mol Cancer Ther. 2021 Feb;20(2):423-437
pubmed: 33273057
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Cancer Treat Rev. 2020 Nov;90:102087
pubmed: 32799062
Virchows Arch. 2019 Aug;475(2):211-221
pubmed: 30972551
Clin Cancer Res. 2008 Jan 15;14(2):494-501
pubmed: 18223224
Oncoimmunology. 2017 Jan 9;6(2):e1258504
pubmed: 28344866
J Innate Immun. 2012;4(1):31-40
pubmed: 21912088
Int J Cancer. 2021 May 1;148(9):2090-2101
pubmed: 33129233
Cell Biochem Biophys. 2013 Jul;66(3):843-50
pubmed: 23340902
J Dermatol Sci. 2010 Mar;57(3):149-54
pubmed: 20060267
Nat Rev Dis Primers. 2016 Dec 01;2:16086
pubmed: 27905473
J Urol. 2012 Jun;187(6):2236-42
pubmed: 22503055
Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8
pubmed: 33301706
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Cancer Res. 2016 Jan 15;76(2):403-17
pubmed: 26634925